SEC Stock Data Quick Answer Zentalis Pharmaceuticals, Inc. reported R&D Expense of $107.30 million for fiscal year 2025. Zentalis Pharmaceuticals, Inc. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $107.30M -36.0% 2024 $167.77M -11.5% 2023 $189.59M +9.8% 2022 $172.73M -1.6% 2021 $175.60M +106.8% 2020 $84.90M +121.2% 2019 $38.39M — Quarterly R&D Expense Quarter Ending … Read more
Quick Answer Zentalis Pharmaceuticals, Inc. reported Stockholders Equity of $216.20 million for fiscal year 2025. Zentalis Pharmaceuticals, Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $216.20M -35.9% 2024 $337.19M -22.9% 2023 $437.28M +0.8% 2022 $433.80M +19.0% 2021 $364.48M +9.3% 2020 $333.38M +554.9% 2019 -$73.28M -326.8% 2018 $32.31M — Quarterly Stockholders … Read more
Quick Answer Zentalis Pharmaceuticals, Inc. reported Cash and Equivalents of $35.99 million for fiscal year 2025. Zentalis Pharmaceuticals, Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $35.99M +6.2% 2024 $33.90M +20.9% 2023 $28.04M -34.9% 2022 $43.07M -27.9% 2021 $59.71M +8.7% 2020 $54.95M -18.3% 2019 $67.25M — Quarterly Cash … Read more
Quick Answer Zentalis Pharmaceuticals, Inc. reported Total Assets of $288.97 million for fiscal year 2025. Zentalis Pharmaceuticals, Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $288.97M -32.9% 2024 $430.34M -22.0% 2023 $551.69M +2.3% 2022 $539.31M +18.7% 2021 $454.51M +24.3% 2020 $365.56M +317.9% 2019 $87.48M — Quarterly Total Assets Quarter Ending … Read more
Quick Answer Zentalis Pharmaceuticals, Inc. reported Diluted EPS of $1.91 per share (loss) for fiscal year 2025. Zentalis Pharmaceuticals, Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$1.91 +18.0% 2024 -$2.33 +47.9% 2023 -$4.47 +0.2% 2022 -$4.48 -20.4% 2021 -$3.72 +11.2% 2020 -$4.19 +48.7% 2019 -$8.16 — Quarterly Diluted EPS … Read more
Quick Answer Zentalis Pharmaceuticals, Inc. reported Net Income of -$137.06 million for fiscal year 2025. Zentalis Pharmaceuticals, Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$137.06M +17.4% 2024 -$165.84M +43.2% 2023 -$292.19M -23.4% 2022 -$236.81M -49.2% 2021 -$158.72M -34.7% 2020 -$117.84M -158.1% 2019 -$45.66M — Quarterly Net Income Quarter Ending … Read more
Quick Answer Zentalis Pharmaceuticals, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2025. Zentalis Pharmaceuticals, Inc. Revenue (ASC 606) — Annual History Fiscal Year Revenue (ASC 606) YoY Change 2025 $0.00 -100.0% 2024 $67.42M — 2023 $0.00 — 2022 $0.00 — Quarterly Revenue (ASC 606) Quarter Ending Revenue (ASC 606) YoY QoQ September … Read more
Quick Answer Zentalis Pharmaceuticals, Inc. reported Total Revenue of $0.00 for fiscal year 2025. Zentalis Pharmaceuticals, Inc. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $0.00 -100.0% 2024 $67.42M — 2023 $0.00 — 2022 $0.00 — Quarterly Total Revenue Quarter Ending Total Revenue YoY QoQ September 30, 2025 $0.00 — — … Read more
Quick Answer Zentalis Pharmaceuticals, Inc. reported Total Revenue of $0.00 for fiscal year 2025. Zentalis Pharmaceuticals, Inc. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $0.00-100.0% $67.42M $0.00 $0.00 — — Revenue (ASC 606) $0.00-100.0% $67.42M $0.00 $0.00 — — Net Income -$137.06M+17.4% -$165.84M+43.2% -$292.19M-23.4% -$236.81M-49.2% -$158.72M-34.7% -$117.84M-158.1% Diluted … Read more
Quick Answer ZION OIL & GAS INC reported Shares Outstanding of 1.16 billion shares for fiscal year 2025. ZION OIL & GAS INC Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 1.16B +19.8% 2024 965.36M +50.8% 2023 640.00M +22.1% 2022 524.23M +43.9% 2021 364.32M +53.5% 2020 237.38M +91.5% 2019 123.97M +86.7% … Read more